INmune Bio Stock

INmune Bio EBIT

The EBIT of INmune Bio (INMB) as of Aug 8, 2026 is -43.00 M USD. In the previous year, EBIT was -29.74 M USD — a change of 44.58% (lower).

EBIT

-43.00 MUSD

YoY

44.58%

Last updated:

In 2026, INmune Bio's EBIT was -43.00 M USD, a 44.58% increase from the -29.74 M USD EBIT recorded in the previous year.

The INmune Bio EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2024
-43.00 base
Jan 1, 2025 (e)
-50.33 base
Jan 1, 2026 (e)
-31.41 base
Jan 1, 2027 (e)
-36.42 base
Jan 1, 2028 (e)
-33.49 base
Jan 1, 2029 (e)
36.28 base
Jan 1, 2030 (e)
89.29 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (M USD)
2031 est -
2030 est 89.29
2029 est 36.28
2028 est -33.49
2027 est -36.42
2026 est -31.41
2025 est -50.33
2024 -43.00
2023 -29.74
2022 -25.95
2021 -29.15
2020 -12.23
2019 -7.76
2018 -12.44
2017 -0.98
2016 -0.23
2015 -0.05
Access this data via the Eulerpool API

INmune Bio Revenue

INmune Bio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
14,000.00 USD
-43.00 M USD
-42.00 M USD
Jan 1, 2025 (e)
51,000.00 USD
-50.33 M USD
-52.07 M USD
Jan 1, 2026 (e)
0.00 USD
-31.41 M USD
-24.88 M USD
Jan 1, 2027 (e)
6.82 M USD
-36.42 M USD
-26.40 M USD
Jan 1, 2028 (e)
31.58 M USD
-33.49 M USD
-21.16 M USD
Jan 1, 2029 (e)
100.73 M USD
36.28 M USD
27.39 M USD
Jan 1, 2030 (e)
176.67 M USD
89.29 M USD
67.53 M USD
Jan 1, 2031 (e)
265.51 M USD
0.00 USD
126.39 M USD

INmune Bio Margins

INmune Bio stock margins

The INmune Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of INmune Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for INmune Bio.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
0.00 %
-307,142.85 %
-300,000.00 %
Jan 1, 2025 (e)
0.00 %
-98,691.00 %
-102,105.60 %
Jan 1, 2026 (e)
0.00 %
- %
- %
Jan 1, 2027 (e)
0.00 %
-534.01 %
-387.07 %
Jan 1, 2028 (e)
0.00 %
-106.03 %
-66.99 %
Jan 1, 2029 (e)
0.00 %
36.01 %
27.19 %
Jan 1, 2030 (e)
0.00 %
50.54 %
38.23 %
Jan 1, 2031 (e)
0.00 %
0.00 %
47.60 %

INmune Bio Stock analysis

What does INmune Bio do? INmune Bio, Inc. is an emerging biotechnology company specializing in the development of immunotherapies for previously incurable diseases. The company was founded in 2015 and is headquartered in La Jolla, California. The company was founded by Dr. RJ Tesi, who was previously a senior scientist at another biotech firm. Dr. Tesi and his research team were frustrated with the disappointing results of existing treatments for a variety of diseases, including cancer, Alzheimer's, and Parkinson's. They decided to explore a new type of immunotherapy that would better address the complexities of the immune system. After years of research and development, INmune Bio has successfully developed several drug candidates, some of which are already being tested in clinical trials. INmune Bio's business model focuses on the invention of safe, affordable, and easy-to-use immunotherapies based on NK and T cells. Their goal is to combat chronic inflammation, glial stress, and neurodegenerative diseases through the use of drug candidates. The company has established strong partnerships with academic and clinical partners both in the US and internationally. INmune Bio is expected to focus on the further development and approval of several groundbreaking therapy options in the coming years. INmune Bio is divided into two divisions: INKmune and XPro1595. The INKmune technology platform is focused on strengthening a key component of the immune system, namely natural killer cells (NK cells). NK cells play an important role in the destruction of abnormal cells such as cancer cells. The INKmune technology aims to support the immune system through a combination of drugs and host metabolism changes, not only applying to cancer cells but also to other diseases such as Alzheimer's. XPro1595 is a drug candidate that is able to stop the inflammatory process by specifically inhibiting the activity of microglia cells in the brain. These cells are activated in many diseases, such as Alzheimer's, autoimmune diseases, or traumatic brain injuries. XPro1595 is intended to slow down the progressive course of these diseases by inhibiting harmful inflammation. INmune Bio currently has one drug candidate in Phase 1b clinical trials, INKmune. INKmune is a novel drug that aims to support the immune system by activating natural killer cells (NK cells). It has been developed to induce a comprehensive immune response to tumors of any kind. XPro1595 has also been developed to be used in various diseases, including Alzheimer's and Parkinson's. The drug is currently in Phase 2 clinical trials. In conclusion, INmune Bio is a biotechnology company specializing in immunotherapies. Their two main divisions, INKmune and XPro1595, aim to modulate the immune system and combat inflammation to treat various diseases. INmune Bio already has drug candidates in clinical development and works closely with academic and clinical partners. The company is expected to expand its portfolio of innovative therapy options and seek approval for additional drugs in the coming years. INmune Bio is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing INmune Bio's EBIT

INmune Bio's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of INmune Bio's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

INmune Bio's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in INmune Bio’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about INmune Bio stock

EBIT of INmune Bio is -43.00 M USD in 2026.

EBIT of INmune Bio changed from -29.74 M USD to -43.00 M USD, representing a 44.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT INmune Bio since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's INmune Bio historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — INmune Bio

All Key Metrics — INmune Bio